Financhill
Buy
52

MAZE Quote, Financials, Valuation and Earnings

Last price:
$16.19
Seasonality move :
--
Day range:
$14.89 - $16.20
52-week range:
$6.71 - $17.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.35x
Volume:
89.3K
Avg. volume:
117.7K
1-year change:
--
Market cap:
$685.7M
Revenue:
$167.5M
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MAZE
Maze Therapeutics
$2.5M -$0.95 -98.11% -1571.33% $23.00
CDT
Conduit Pharmaceuticals
-- -- -- -- --
IFRX
InflaRx NV
$24.7K -$0.23 256.48% -10.49% $3.62
LENZ
LENZ Therapeutics
$714.3K -$0.54 -- -26.67% $44.50
LIMN
Liminatus Pharma
-- -- -- -- --
ORKA
Oruka Therapeutics
-- -$0.43 -- -42.18% $39.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MAZE
Maze Therapeutics
$16.01 $23.00 $685.7M -- $0.00 0% --
CDT
Conduit Pharmaceuticals
$2.27 -- $1.8M -- $0.00 0% --
IFRX
InflaRx NV
$0.81 $3.62 $55.1M -- $0.00 0% 268.90x
LENZ
LENZ Therapeutics
$32.75 $44.50 $921.8M -- $1.03 0% --
LIMN
Liminatus Pharma
-- -- -- -- $0.00 0% --
ORKA
Oruka Therapeutics
$14.70 $39.50 $550.4M -- $19.36 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MAZE
Maze Therapeutics
-- 0.000 -- --
CDT
Conduit Pharmaceuticals
-- 1.154 -- --
IFRX
InflaRx NV
-- 1.115 -- 3.85x
LENZ
LENZ Therapeutics
-- 0.499 -- --
LIMN
Liminatus Pharma
-- 0.000 -- --
ORKA
Oruka Therapeutics
-- -0.228 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MAZE
Maze Therapeutics
-- -- -- -- -- --
CDT
Conduit Pharmaceuticals
-- -$4M -- -- -- -$4.3M
IFRX
InflaRx NV
-$9.8K -$13.7M -56.78% -56.78% 1207051.66% -$14.8M
LENZ
LENZ Therapeutics
-- -$16.9M -- -- -- -$16.2M
LIMN
Liminatus Pharma
-- -- -- -- -- --
ORKA
Oruka Therapeutics
-- -$25.1M -- -- -- -$20.9M

Maze Therapeutics vs. Competitors

  • Which has Higher Returns MAZE or CDT?

    Conduit Pharmaceuticals has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat Conduit Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MAZE
    Maze Therapeutics
    -- -- --
    CDT
    Conduit Pharmaceuticals
    -- -$19.80 --
  • What do Analysts Say About MAZE or CDT?

    Maze Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 43.66%. On the other hand Conduit Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics has higher upside potential than Conduit Pharmaceuticals, analysts believe Maze Therapeutics is more attractive than Conduit Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MAZE
    Maze Therapeutics
    4 0 0
    CDT
    Conduit Pharmaceuticals
    0 0 0
  • Is MAZE or CDT More Risky?

    Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Conduit Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MAZE or CDT?

    Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conduit Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics pays -- of its earnings as a dividend. Conduit Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MAZE or CDT?

    Maze Therapeutics quarterly revenues are --, which are smaller than Conduit Pharmaceuticals quarterly revenues of --. Maze Therapeutics's net income of -- is lower than Conduit Pharmaceuticals's net income of -$5.1M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while Conduit Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for Conduit Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MAZE
    Maze Therapeutics
    -- -- -- --
    CDT
    Conduit Pharmaceuticals
    -- -- -- -$5.1M
  • Which has Higher Returns MAZE or IFRX?

    InflaRx NV has a net margin of -- compared to Maze Therapeutics's net margin of -14092.9%. Maze Therapeutics's return on equity of -- beat InflaRx NV's return on equity of -56.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    MAZE
    Maze Therapeutics
    -- -- --
    IFRX
    InflaRx NV
    -5376.61% -$0.14 $63.9M
  • What do Analysts Say About MAZE or IFRX?

    Maze Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 43.66%. On the other hand InflaRx NV has an analysts' consensus of $3.62 which suggests that it could grow by 344.48%. Given that InflaRx NV has higher upside potential than Maze Therapeutics, analysts believe InflaRx NV is more attractive than Maze Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MAZE
    Maze Therapeutics
    4 0 0
    IFRX
    InflaRx NV
    5 1 0
  • Is MAZE or IFRX More Risky?

    Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.054%.

  • Which is a Better Dividend Stock MAZE or IFRX?

    Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MAZE or IFRX?

    Maze Therapeutics quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of -$450. Maze Therapeutics's net income of -- is lower than InflaRx NV's net income of -$8.7M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus 268.90x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MAZE
    Maze Therapeutics
    -- -- -- --
    IFRX
    InflaRx NV
    268.90x -- -$450 -$8.7M
  • Which has Higher Returns MAZE or LENZ?

    LENZ Therapeutics has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat LENZ Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MAZE
    Maze Therapeutics
    -- -- --
    LENZ
    LENZ Therapeutics
    -- -$0.53 --
  • What do Analysts Say About MAZE or LENZ?

    Maze Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 43.66%. On the other hand LENZ Therapeutics has an analysts' consensus of $44.50 which suggests that it could grow by 35.88%. Given that Maze Therapeutics has higher upside potential than LENZ Therapeutics, analysts believe Maze Therapeutics is more attractive than LENZ Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MAZE
    Maze Therapeutics
    4 0 0
    LENZ
    LENZ Therapeutics
    5 0 0
  • Is MAZE or LENZ More Risky?

    Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MAZE or LENZ?

    Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Maze Therapeutics pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MAZE or LENZ?

    Maze Therapeutics quarterly revenues are --, which are smaller than LENZ Therapeutics quarterly revenues of --. Maze Therapeutics's net income of -- is lower than LENZ Therapeutics's net income of -$14.6M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MAZE
    Maze Therapeutics
    -- -- -- --
    LENZ
    LENZ Therapeutics
    -- -- -- -$14.6M
  • Which has Higher Returns MAZE or LIMN?

    Liminatus Pharma has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat Liminatus Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MAZE
    Maze Therapeutics
    -- -- --
    LIMN
    Liminatus Pharma
    -- -- --
  • What do Analysts Say About MAZE or LIMN?

    Maze Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 43.66%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Maze Therapeutics has higher upside potential than Liminatus Pharma, analysts believe Maze Therapeutics is more attractive than Liminatus Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    MAZE
    Maze Therapeutics
    4 0 0
    LIMN
    Liminatus Pharma
    0 0 0
  • Is MAZE or LIMN More Risky?

    Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MAZE or LIMN?

    Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Maze Therapeutics pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MAZE or LIMN?

    Maze Therapeutics quarterly revenues are --, which are smaller than Liminatus Pharma quarterly revenues of --. Maze Therapeutics's net income of -- is lower than Liminatus Pharma's net income of --. Notably, Maze Therapeutics's price-to-earnings ratio is -- while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MAZE
    Maze Therapeutics
    -- -- -- --
    LIMN
    Liminatus Pharma
    -- -- -- --
  • Which has Higher Returns MAZE or ORKA?

    Oruka Therapeutics has a net margin of -- compared to Maze Therapeutics's net margin of --. Maze Therapeutics's return on equity of -- beat Oruka Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MAZE
    Maze Therapeutics
    -- -- --
    ORKA
    Oruka Therapeutics
    -- -$0.40 --
  • What do Analysts Say About MAZE or ORKA?

    Maze Therapeutics has a consensus price target of $23.00, signalling upside risk potential of 43.66%. On the other hand Oruka Therapeutics has an analysts' consensus of $39.50 which suggests that it could grow by 168.71%. Given that Oruka Therapeutics has higher upside potential than Maze Therapeutics, analysts believe Oruka Therapeutics is more attractive than Maze Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MAZE
    Maze Therapeutics
    4 0 0
    ORKA
    Oruka Therapeutics
    7 0 0
  • Is MAZE or ORKA More Risky?

    Maze Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of -0.343, suggesting its less volatile than the S&P 500 by 134.274%.

  • Which is a Better Dividend Stock MAZE or ORKA?

    Maze Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. Maze Therapeutics pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MAZE or ORKA?

    Maze Therapeutics quarterly revenues are --, which are smaller than Oruka Therapeutics quarterly revenues of --. Maze Therapeutics's net income of -- is lower than Oruka Therapeutics's net income of -$21M. Notably, Maze Therapeutics's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Maze Therapeutics is -- versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MAZE
    Maze Therapeutics
    -- -- -- --
    ORKA
    Oruka Therapeutics
    -- -- -- -$21M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
71
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
61
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
75
MP alert for Jul 16

MP Materials [MP] is up 20.3% over the past day.

Sell
38
NAIL alert for Jul 16

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is down 11.72% over the past day.

Sell
39
EHC alert for Jul 16

Encompass Health [EHC] is down 10.46% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock